论文部分内容阅读
目的观察大黄附子汤联合双歧三联活菌胶囊对慢性复发型结肠炎患者的临床疗效。方法从常州市中医医院、南京中医药大学附属医院和苏州市中医医院肛肠科门诊病人中选取符合纳入标准的患者90例,随机数字表法分为治疗A组(口服双歧三联活菌胶囊,2粒/次,3次/d)30例,治疗B组(在治疗A组基础上,口服大黄附子汤,早晚各1次)30例和对照组(美沙拉嗪缓释颗粒剂,1 g/次,3次/d)30例,三组疗程均为3个月。比较三组治疗前后临床疗效,粪钙卫蛋白、C反应蛋白和红细胞沉降率的变化趋势,炎症性肠病评价量表评分、停药1个月后的复发率及不良反应。结果与对照组相比,治疗B组在临床综合疗效,粪钙卫蛋白、C反应蛋白和红细胞沉降率、停药1个月后复发率方面经统计学比较均有明显差异(P<0.05,P<0.01)。结论大黄附子汤联合双歧三联活菌胶囊治疗慢性复发型结肠炎患者临床疗效显著,且无明显不良反应,值得临床推广应用。
Objective To observe the clinical efficacy of rhubarb and aconite soup combined with bifid triple viable capsule in patients with chronic recurrent colitis. Methods Ninety patients who met the inclusion criteria were selected from Changzhou Traditional Chinese Medicine Hospital, Nanjing University of Chinese Medicine Affiliated Hospital and Suzhou Traditional Chinese Medicine Hospital. Patients were randomly divided into treatment group A (oral Bifid triple viable capsule, 2 capsules / time, 3 times / d) 30 cases, treatment group B (in the treatment group A, oral rhubarb aconite soup, morning and evening 1) 30 cases and the control group (mesalazine sustained release granules, 1 g / Times, 3 times / d) 30 cases, three courses were 3 months. The clinical curative effect, the change trend of fecal calprotectin, C-reactive protein and erythrocyte sedimentation rate, inflammatory bowel disease evaluation scale score, recurrence rate and adverse reactions after 1 month withdrawal were compared between the three groups before and after treatment. Results Compared with the control group, there was a significant difference (P <0.05, P <0.05) in the clinical efficacy, the fecal calprotectin, C-reactive protein and erythrocyte sedimentation rate, P <0.01). Conclusion Rhubarb aconite soup combined with bifid triple viable capsules in patients with chronic recurrent colitis clinical significant effect, and no significant adverse reactions, it is worth promoting the clinical application.